Abstract
The problem of DR-TB especially MDR-TB/RR-TB, Pre-XDR TB, and XDR TB is menacing the world in a fearsome manner. The treatment of patients with such complicated forms of TB is fraught with difficulties owing to the toxicity of second-line drugs and decreased efficacy, not to mention poor compliance by patients keeping in view the adverse effects and long duration of treatment. To add to all these strictures in the successful outcome of DR-TB outcomes, the phenomenon of Cross-Resistance amongst anti-tubercular drugs has also to be reckoned with. In this review, we have tried to address this particular aspect which plays one of the key roles in the final treatment outcome of patients with such complicated forms of TB.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
